<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156261">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736592</url>
  </required_header>
  <id_info>
    <org_study_id>SG1/002/11</org_study_id>
    <nct_id>NCT01736592</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Long Term Safety, Tolerability and Biological Activity of StarGen™ in Patients With Stargardt's Macular Degeneration</brief_title>
  <official_title>An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of StarGen™ in Patients With Stargardt's Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford BioMedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxford BioMedica</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the long term safety of an experimental gene transfer
      agent, StarGen™, designed to treat Stargardt Macular Degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">October 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2030</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>The incidence of Adverse Events</measure>
    <time_frame>15 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of patients with treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delay in retinal degeneration</measure>
    <time_frame>15 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change from baseline function relative to the contralateral eye utilising retinal analytical techniques</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Stargardt Disease</condition>
  <arm_group>
    <arm_group_label>Long Term Follow up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Long Term follow up of patients who received StarGen™  in a previous study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>StarGen</intervention_name>
    <arm_group_label>Long Term Follow up</arm_group_label>
    <other_name>Long Term follow up of patients who received StarGen™ in a previous study</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have received a subretinal injection of StarGen™

          -  Must have completed protocol SG1/001/10 to Week 48 or undergone an early
             discontinuation visit.

        Exclusion Criteria:

          -  Did not receive StarGen™as part of the SG1/001/10 protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José-Alain Sahel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre National d'Ophtalmologie des Quinze-Vingts</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre National d'Ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
